Virtual Reality Smartphone-Based Intervention for Smoking Cessation: Pilot Randomized Controlled Trial on Initial Clinical Efficacy and Adherence

Abstract

Background Obstacles to current tobacco cessation programs include limited access and adherence to effective interventions. Digital interventions offer a great opportunity to overcome these difficulties, yet virtual reality has not been used as a remote and self-administered tool to help increase adherence and effectiveness of digital interventions for tobacco cessation. Objective This study aimed to evaluate participant adherence and smoking cessation outcomes in a pilot randomized controlled trial of the digital intervention Mindcotine (MindCotine Inc) using a self-administered treatment of virtual reality combined with mindfulness. Methods A sample of 120 participants was recruited in the city of Buenos Aires, Argentina (mean age 43.20 years, SD 9.50; 57/120, 47.5% female). Participants were randomly assigned to a treatment group (TG), which received a self-assisted 21-day program based on virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists, or a control group (CG), which received the online version of the smoking cessation manual from the Argentine Ministry of Health. Follow-up assessments were conducted by online surveys at postintervention and 90-day follow-up. The primary outcome was self-reported abstinence at postintervention, with missing data assumed as still smoking. Secondary outcomes included sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit. Results Follow-up rates at day 1 were 93% (56/60) for the TG and 100% (60/60) for the CG. At postintervention, the TG reported 23% (14/60) abstinence on that day compared with 5% (3/60) in the CG. This difference was statistically significant (χ21=8.3; P=.004). The TG reported sustained abstinence of 33% (20/60) at 90 days. Since only 20% (12/60) of participants in the CG completed the 90-day follow-up, we did not conduct a statistical comparison between groups at this follow-up time point. Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005). A total of 41% (23/56) of participants completed the treatment in the time frame recommended by the program. Conclusions Results provide initial support for participant adherence to and efficacy of Mindcotine and warrant testing the intervention in a fully powered randomized trial. However, feasibility of trial follow-up assessment procedures for control group participants needs to be improved. Further research is needed on the impact of VR-MET on long-term outcomes. Trial Registration ISRCTN Registry ISRCTN50586181; http://www.isrctn.com/ISRCTN50586181

Clinical Relevance of Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: A Systematic Review and Future Perspective

“…Four of the ten VRET studies found null results at all [51,52,54,55], while two reported negative effects of VRET [47,49]. Five studies found a reduction in craving after VRET [21,46,48,49,56]. Only three of these studies reported effect sizes (ηp 2 = 0.47-0.76 or d = 0.44).…”

Virtual Reality-Based Treatment Approaches in the Field of Substance Use Disorders

“…A small sample size (n = 11) might be a limitation to the findings but a post-hoc withinsubject analysis found a significant decrease in subjective craving during and after each session only for the experimental group but not for the placebo group. Further, individuals with nicotine addiction (n = 60) practicing mindfulness during a VR exposure therapy as part of a 21-day multimodal smartphone-based intervention achieved a significant higher abstinence rate at the end of the intervention compared to a control group (n = 60) in a randomized controlled trial [52]. This study showed good adherence rates (93%) for this outpatient treatment group for the use of a VR cardboard headset, which implies generalization to general patient populations.…”

Extended Reality for Enhanced Telehealth During and Beyond COVID-19: Viewpoint

“…XR telehealth allowed providers to deliver services into patients’ own homes and naturalistic environments, which has long been a limitation of traditional clinical treatment [ 100 ]. Low-cost, off-the-shelf hardware and royalty-free software for therapy and rehabilitation made XR telehealth an economically feasible solution [ 101 , 102 ]. XR telehealth training and education also rose in response to COVID-19.…”

“…However, high-end VR setups can be purchased today for use in one’s own home for about US $3000 total with a growing variety of free-to-use and open-source software [ 196 ]. Low-end XR (eg, Google Cardboard VR, Holokit AR) costs as little as US $15-$50, involves the use of smartphones many people already own, and has been applied with clinically significant treatment success [ 102 , 197 ]. Costs are anticipated to continue decreasing as consumer XR hardware becomes more established [ 198 ].…”